Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer, for the month of July 2019. The filing date is July 8, 2019. The document serves to incorporate by reference a press release regarding a finalized agreement with Washington University (WU).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes and Operational Updates
The primary material event disclosed is the finalization of an "Accelerated Clinical Trial Agreement" between Cellect Biotechnology and Washington University. This agreement is intended to advance the company's clinical development efforts.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the context of the clinical trial agreement. The press release is incorporated into the company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific terms and scope of the Accelerated Clinical Trial Agreement with Washington University.
- Review the full text of the press release (Exhibit 99.1) for details on the clinical trial timeline and objectives.
- Confirm the impact of this agreement on the company's existing Registration Statements (Form S-8 and Form F-3).
- Note that no financial data is included in this specific filing; refer to recent Form 20-F filings for financial metrics.